Welcome to our dedicated page for Sunshine Biopharma SEC filings (Ticker: SBFMW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Sunshine Biopharma's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Sunshine Biopharma's regulatory disclosures and financial reporting.
Sunshine Biopharma Inc. is initiating an at-the-market common stock offering of up to $4,000,000 under a Sales Agreement with Aegis Capital Corp., acting as exclusive sales agent. Shares may be sold from time to time on Nasdaq as defined in Rule 415.
The company will pay Aegis a 3.0% cash commission on gross proceeds and reimburse specified expenses, and Aegis will be deemed an underwriter. Net proceeds are intended for general corporate purposes, including working capital. Under General Instruction I.B.6 of Form S-3, primary offerings are limited to one-third of non-affiliate market value while it remains below $75 million.
Sunshine Biopharma Inc. entered into an At-The-Market Issuance Sales Agreement with Aegis Capital Corp., allowing the company to sell shares of its common stock from time to time for an aggregate offering price of up to $4,000,000 in at-the-market offerings through or to Aegis as exclusive sales agent.
Sales may be effected directly on or through the Nasdaq Capital Market or other existing trading markets under Rule 415(a)(4). Aegis will receive a 3.0% commission on gross proceeds plus certain reimbursed expenses. Neither party is obligated to transact, and both may terminate the agreement. The shares will be issued under the company’s shelf registration statement on Form S-3 (File No. 333-284142), effective January 15, 2025, and a July 20, 2026 prospectus supplement.
Sunshine Biopharma Inc., through its wholly owned subsidiary Nora Pharma Inc., entered into an agreement of transaction and mutual release with Nora’s former president, Malek Chamoun, on July 8, 2026. Under this agreement, Sunshine Biopharma agreed to pay Mr. Chamoun CAD$1,500,000 (approximately US$1,058,565) in full and final settlement of a dispute between the parties. The agreement functions as a comprehensive release, aiming to conclude outstanding claims between the company, Nora, and Mr. Chamoun.
Sunshine Biopharma Inc. ownership disclosure: Alta Partners LLC reports beneficial ownership of 200,000 shares of common stock, representing 8.6% of the class as of 07/08/2026. The filing states these shares are issuable upon exercise of outstanding warrants and lists Sole Voting and Sole Dispositive Power of 200,000 shares.
Sunshine Biopharma Inc. delivered an information statement reporting that holders of a majority of voting power approved by written consent certain Warrant Stockholder Approval Provisions for the Series C Warrants issued in a May 19, 2026 public offering. The approval was obtained from Dr. Steve N. Slilaty, who held 86.0% of voting power as of May 28, 2026.
The Offering issued 1,116,000 Common Units and 84,000 Pre-Funded Units (aggregate gross proceeds of approximately $6.0 million) and included Series C Warrants exercisable at an initial price of $5.00 per share. The information statement notes a 10-for-1 reverse split effective June 1, 2026 and states the Warrant Stockholder Approval will become effective 20 days after mailing this statement.
Sunshine Biopharma Inc. reports that its majority stockholder, CEO Dr. Steve N. Slilaty, approved by written consent several actions tied to the company’s recent public offering that closed on May 19, 2026. The approval covers issuing more than twenty percent of the outstanding common shares at a deemed discount to the Nasdaq Minimum Price and allows certain exercise price and share-count adjustments for Series C Warrants in connection with a Share Combination Event or voluntary exercise price changes. The consent becomes effective 20 days after a definitive information statement is mailed to stockholders, with Dr. Slilaty holding approximately 86% of the total voting power.
L1 Capital Global Opportunities Master Fund, Ltd. reports beneficial ownership of 1,000,000 Common Units of Sunshine Biopharma Inc., representing 5.83% of the class.
The filing states the percentage is based on 16,165,945 Common Units outstanding as referenced from the issuer's prospectus and Form 8-K filings dated May 19, 2026. The filing notes 2,000,000 Series C Warrants exercisable into common stock, which are subject to a 4.99% beneficial ownership limitation. The reporting person is organized in the Cayman Islands and is represented by Directors David Feldman and Joel Arber; the cover signature is by Mr. Feldman.
Sunshine Biopharma Inc. Schedule 13G: Reporting persons led by Michael Bigger reported beneficial ownership of 805,000 shares of Common Stock, equal to 4.73% of 17,005,945 shares outstanding as of the issuer prospectus. The filing states the Reporting Persons sold all their Common Stock as of May 19, 2026.
The filing also lists warrants (Pre-Funded, Series B, Series C) that were subject to 4.99% beneficial ownership limitations and were excluded from the reported beneficial ownership counts.
Sunshine Biopharma Inc. completed a best efforts public unit offering, raising approximately $6.0 million in gross proceeds through 12,000,000 Common Units or Pre-Funded Units priced at $0.50 per Common Unit.
Each unit includes one share of common stock or one Pre-Funded Warrant plus two Series C Warrants, each Series C Warrant exercisable at $0.50 per share for five years. The Pre-Funded Warrants are immediately exercisable at $0.00001 per share until fully exercised. If all Series C Warrants are exercised on a cash basis, the Company could receive up to an additional approximately $12.0 million in gross proceeds.
The Company intends to use net proceeds for general corporate purposes and working capital, supporting its Canadian generic drug portfolio and proprietary programs in liver cancer and SARS-related coronavirus infections.
Sunshine Biopharma reported Q1 2026 sales of $8.1 million, down about 9% from $8.9 million a year earlier, mainly due to the termination of certain distribution agreements. Gross profit was $2.2 million with a margin of 27%, versus $2.7 million and 30.7% in Q1 2025.
The company posted a net loss of $1.24 million, slightly wider than the prior-year loss of $1.18 million, or $(0.25) per share on 4.9 million weighted-average shares. Operating expenses fell to $3.6 million from $4.0 million as accounting, consulting, marketing, office and R&D costs declined, partly offset by higher salaries and legal fees.
Cash and equivalents were $6.9 million at March 31, 2026, with total assets of $27.9 million and no debt beyond lease liabilities. Management estimates current cash and operating cash flows can fund the business for about 17 months while it works to grow Nora Pharma’s Canadian generic drug sales and advance two proprietary programs in liver cancer mRNA and a PLpro inhibitor for SARS coronavirus infections.